A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors
This is a first-in-human study to learn about the study drug DCSZ11, given alone and in combination in patients with advanced or metastatic solid tumors.
Why this Research Matters
DCSZ11 is being tested to treat people who have advanced or metastatic solid tumors. The study will include a dose escalation phase and a dose expansion phase.
Who can Participate
Adult
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Study ID
Protocol Number: 23-1383
More information available at ClinicalTrials.gov: NCT05785754
Meet the Team
Principal Investigator
Categories
Locations
-
University of Colorado Hospital
- Outpatient CTRC
- CTRC Inpatient